4 Healthcare Stock Stories Prescribed for Weekend Reading

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Vivus (NASDAQ:VVUS): Current price $12.36

Vivus announced Friday that the European Medicines Agency’s Committee for Medicinal Products for Human Use has confirmed its October 18th decision to decline the Marketing Authorization Application for Qsiva (phentermine/topiramate ER) designed for the treatment of obesity in the European Union. The firm had requested a re-examination of the opinion, but considering the grounds for this request, CHMP once again refused the marketing authorization on Thursday. In its deliberation over the Qsiva MAA, CHMP said that a pre-approval cardiovascular outcomes trial would be required to establish long-term safety.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

vvus

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business